| 000 | 01890 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250515155632.0 | ||
| 264 | 0 | _c20090716 | |
| 008 | 200907s 0 0 eng d | ||
| 022 | _a1078-0432 | ||
| 024 | 7 |
_a10.1158/1078-0432.CCR-08-1261 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBerenson, James R | |
| 245 | 0 | 0 |
_aA phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma. _h[electronic resource] |
| 260 |
_bClinical cancer research : an official journal of the American Association for Cancer Research _cFeb 2009 |
||
| 300 |
_a1069-75 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aBoronic Acids _xadministration & dosage |
| 650 | 0 | 4 | _aBortezomib |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 |
_aEthylenediamines _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMaximum Tolerated Dose |
| 650 | 0 | 4 |
_aMultiple Myeloma _xtherapy |
| 650 | 0 | 4 |
_aOrganophosphonates _xadministration & dosage |
| 650 | 0 | 4 | _aPlatelet Count |
| 650 | 0 | 4 |
_aPyrazines _xadministration & dosage |
| 650 | 0 | 4 |
_aRadioisotopes _xadministration & dosage |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 |
_aSamarium _xadministration & dosage |
| 700 | 1 | _aYellin, Ori | |
| 700 | 1 | _aPatel, Ravi | |
| 700 | 1 | _aDuvivier, Herb | |
| 700 | 1 | _aNassir, Youram | |
| 700 | 1 | _aMapes, Russell | |
| 700 | 1 | _aAbaya, Christina DiLauro | |
| 700 | 1 | _aSwift, Regina A | |
| 773 | 0 |
_tClinical cancer research : an official journal of the American Association for Cancer Research _gvol. 15 _gno. 3 _gp. 1069-75 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1158/1078-0432.CCR-08-1261 _zAvailable from publisher's website |
| 999 |
_c18633209 _d18633209 |
||